/KTTA
KTTA Stock - Pasithea Therapeutics Corp.
Healthcare|BiotechnologyNASDAQ
$1.16+5.45%
+$0.06 (+5.45%) • Dec 19
87
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.87
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+158.6%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KTTA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.15 – $1.17
TARGET (TP)$3.00
STOP LOSS$1.07
RISK/REWARD1:20.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.21
52W High$3.85
52W Low$0.28
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $15,062 | N/A |
| Gross Profit | N/A | N/A | $-5,094 | $-2,213 | N/A |
| Gross Margin | N/A | N/A | N/A | -14.7% | N/A |
| Operating Income | $-14,249,962 | $-15,979,361 | $-12,588,971 | $-4,507,413 | $-61,476 |
| Net Income | $-13,904,584 | $-15,961,658 | $-13,936,452 | $-2,173,521 | $-61,476 |
| Net Margin | N/A | N/A | N/A | -14430.5% | N/A |
| EPS | $-12.69 | $-12.65 | $-10.34 | $-1.89 | $-0.06 |
Company Overview
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
KTTABeat Rate
56%
Last 9 quarters
Avg Surprise
-655.8%
EPS vs Estimate
Beats / Misses
5/4
Last 12 quarters
Latest EPS
$-0.41
Q4 2025
EPS Surprise History
Q1 24
-27.5%
$-4.85vs$-3.80
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-0.18 | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-0.41 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-0.66 | — | — |
Q2 2025 | May 15, 2025 | — | $-1.61 | — | — |
Q1 2025 | Mar 24, 2025 | — | $-2.41 | — | — |
Q4 2024 | Nov 13, 2024 | — | $-2.87 | — | — |
Q3 2024 | Aug 13, 2024 | — | $-3.71 | — | — |
Q2 2024 | May 14, 2024 | — | $-3.70 | — | — |
Q1 2024 | Mar 28, 2024 | $-3.80 | $-4.85 | -27.5% | ✗ MISS |
Q4 2023 | Dec 29, 2023 | $-3.60 | $-2.87 | +20.2% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-3.40 | $-2.88 | +15.3% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-3.40 | $-211.05 | -6107.3% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-3.40 | $-3.00 | +11.9% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-3.40 | $-3.45 | -1.6% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-2.20 | $-0.08 | +96.5% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.02 | $-0.07 | -250.0% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-0.05 | $0.12 | +340.0% | ✓ BEAT |
Q4 2021 | Nov 18, 2021 | — | $-0.17 | — | — |
Q3 2021 | Sep 16, 2021 | — | $-0.04 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.07 | — | — |
Latest News
HC Wainwright & Co. Initiates Coverage On Pasithea Therapeutics with Buy Rating, Announces Price Target of $3
📈 PositiveBenzinga•Dec 8, 2025, 12:44 PM
Pasithea Therapeutics Form4 Filing Shows CEO Tiago Marques Bought 33,333 Shares At An Average Price Of $0.75/Share
📈 PositiveBenzinga•Dec 1, 2025, 01:59 PM
Pasithea Therapeutics shares are trading higher after the company priced an 80M-share public offering at $0.75 per share.
➖ NeutralBenzinga•Nov 28, 2025, 05:24 PM
Pasithea Therapeutics Announces Pricing Of Public Offering Of 80M Shares At Offering Price Of $0.75/Shr Of Common Stock
➖ NeutralBenzinga•Nov 28, 2025, 02:25 PM
Pasithea Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 115.36%
📈 PositiveBenzinga•Nov 26, 2025, 03:13 PM
Pasithea Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 113.29%
📈 PositiveBenzinga•Nov 26, 2025, 02:53 PM
Pasithea Therapeutics Awarded $1M By ALS Association
📈 PositiveBenzinga•Nov 25, 2025, 12:07 PM
Shares of Pasithea Therapeutics are trading higher. The company announced PK and PD data from Cohort 7 in its ongoing first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation, or in patients who have failed prior BRAF/MEK inhibition.
📈 PositiveBenzinga•Nov 24, 2025, 07:40 PM
Pasithea Reports Results For Pill Aimed At Treating Hard-To-Manage Genetic And Cancer Disorders
➖ NeutralBenzinga•Nov 24, 2025, 12:14 PM
Pasithea Therapeutics Announces Tablet PK Data From Ongoing Phase 1/1b Open-Label Study Evaluating PAS-004 In Adult Patients With Neurofibromatosis Type 1
➖ NeutralBenzinga•Nov 21, 2025, 05:40 PM
Pasithea Therapeutics shares are trading lower. The company announced interim Phase 1 data from its ongoing first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation, or in patients who have failed prior BRAF/MEK inhibition.
📉 NegativeBenzinga•Nov 21, 2025, 02:07 PM
Pasithea Therapeutics shares are trading lower. The company announced interim Phase 1 data from its ongoing first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation, or in patients who have failed prior BRAF/MEK inhibition.
📉 NegativeBenzinga•Nov 20, 2025, 09:33 PM
Pasithea Therapeutics Announces Phase 1 Data From Its Ongoing First-In-Human Trial Evaluating PAS-004; Partial Response Observed In A MEK-Rechallenge 3rd-line Melanoma Patient With Braf V600e Mutation Who Remains On Trial For More Than 11 Months; PAS-004 Has Been Well-Tolerated With All Treatment
📈 PositiveBenzinga•Nov 20, 2025, 09:06 PM
Pasithea Therapeutics Q3 EPS $(0.41) Up From $(2.87) YoY
📈 PositiveBenzinga•Nov 13, 2025, 10:34 PM
Pasithea Therapeutics Activates New U.S. Clinical Facility For Its Current Phase 1/1b Open-label Trial Evaluating Pas-004 In Adult Patients With Neurofibromatosis Type 1
📈 PositiveBenzinga•Nov 4, 2025, 12:05 PM
Pasithea Therapeutics Activates South Korea Sites For Phase 1/1b Trial Of PAS-004 In Adult NF1 Patients With Plexiform Neurofibromas
📈 PositiveBenzinga•Sep 16, 2025, 11:19 AM
External Safety Review Committee Recommended Pasithea Therapeutics' Phase 1/1b Study To Assess PAS-004 For Neurofibromatosis Type 1 To Proceed To Cohort 2, 8mg Tablet, Without Modification, Initial Interim Data From First Two Cohorts Expected In Q1 2026
📈 PositiveBenzinga•Sep 8, 2025, 11:08 AM
Frequently Asked Questions about KTTA
What is KTTA's current stock price?
Pasithea Therapeutics Corp. (KTTA) is currently trading at $1.16 per share. The stock has moved +5.45% today.
What is the analyst price target for KTTA?
The average analyst price target for KTTA is $3.00, based on 1 analyst.
What sector is Pasithea Therapeutics Corp. in?
Pasithea Therapeutics Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KTTA's market cap?
Pasithea Therapeutics Corp. has a market capitalization of $0.01 billion, making it a small-cap company.
Does KTTA pay dividends?
No, Pasithea Therapeutics Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAIM
AIM ImmunoTech Inc.
$1.42
Mkt Cap: $0.0B
CYCN
Cyclerion Therapeutics, Inc.
$1.45
Mkt Cap: $0.0B
IBO
Impact BioMedical Inc.
$0.65
Mkt Cap: $0.0B
KALA
KALA BIO, Inc.
$0.62
Mkt Cap: $0.0B
NBY
NovaBay Pharmaceuticals, Inc.
$5.30
Mkt Cap: $0.0B
PLRZ
Polyrizon Ltd.
$9.43
Mkt Cap: $0.0B
QNRX
Quoin Pharmaceuticals, Ltd.
$14.20
Mkt Cap: $0.0B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
VIVS
VivoSim Labs, Inc.
$1.98
Mkt Cap: $0.0B
VYNE
VYNE Therapeutics Inc.
$0.59
Mkt Cap: $0.0B
Explore stocks similar to KTTA for comparison